0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Protein > NKG2A > NKA-C5245

Cynomolgus NKG2A / CD159a Protein, His Tag

Order Now

  • Sinónimo
    NKG2A,CD159a,KLRC1,NK cell receptor A
  • Fuente
    Cynomolgus NKG2A, His Tag (NKA-C5245) is expressed from human 293 cells (HEK293). It contains AA Pro 94 - Leu 233 (Accession # Q68VD2-1).
  • Caracterización molecular
    Online(Pro 94 - Leu 233) Q68VD2-1

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 17.9 kDa. The protein migrates as 27-37 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxina
    Less than 1.0 EU per μg by the LAL method.
  • Pureza

    >90% as determined by SDS-PAGE.

  • Formulación

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitución

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Almacenamiento

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Cynomolgus NKG2A, His Tag (Cat. No. NKA-C5245) SDS-PAGE gel

Cynomolgus NKG2A, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Antecedentes
    NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €350.00

Price(EUR) : €2570.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:5 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje